Healthy Clinical Trial
Official title:
A Phase I Study of the Safety and Immunogenicity of a West Nile Virus Recombinant DNA Plasmid Vaccine, VRC-WNVDNA017-00 VP, in Healthy Adult Volunteers
This study will test the safety of an experimental vaccine intended to prevent West Nile
virus (WNV) infection and determine if it causes side effects. WNV symptoms may vary from
fever and headache, to a polio-like syndrome with paralysis. Infection rarely results in
death. The vaccine used in this study contains DNA that instructs the body to produce a small
amount of a protein found in WNV. If the body creates resistance or immunity to these
proteins, then the vaccine may protect against WNV. Study participants cannot get WNV from
the vaccine.
Healthy volunteers between 18 years and 50 years of age may be eligible for this study.
Candidates are screened with a medical history, physical examination, and blood and urine
tests, including a pregnancy test for women who can become pregnant. Patients undergo the
following tests and procedures:
- Vaccine injections: Vaccines are given as injections in the upper arm, using a
needleless system called the Biojector 2000. The first injection is on study day 0, the
second on day 28 (+/-) 7 days, and the third on day 56 (+/-) 7 days. There must be at
least 21 days between injections. The pregnancy test for women of childbearing potential
is repeated the day of each vaccine injection.
- Diary card: Participants are given a 5-day diary card after each injection to record
their temperature and any symptoms and side effects they may experience for up to 5 days
after the injection. The diary cards are returned to the clinic at visits scheduled 2
weeks after each injection. Side effects and symptoms also must be reported immediately
to a study nurse or doctor, and a clinic visit may be required for an examination.
- Clinic visits: At day 0 and weeks 2, 4, 6, 8, 10, 12, 24 and 32, participants have a
medical history, physical examination (if needed) and blood tests. Vital signs and
weight are also recorded. Lymph nodes are examined at day 0 and weeks 2, 4, 6, 8, 10 and
12, and urine samples are collected at day 0 and weeks 2, 4, 6, 8 and 10.
Some of the blood drawn during this study is used for genetic tests to see if different types
of immune response to a vaccine are related to genetic differences in people.
Study Design: This is a Phase I open label study to evaluate safety, tolerability, and immune
response of a recombinant DNA vaccine, VRC-WNVDNA017-00-VP. The hypothesis is that this
regimen will be safe for human administration and elicit immune responses to the West Nile
virus. The primary objective is to evaluate the safety and tolerability in humans of the
investigational vaccine. Secondary and exploratory objectives are related to the
immunogenicity of the study vaccine.
Product Description: VRC-WNVDNA017-00-VP is composed of a single closed circular DNA plasmid
that encodes the WNV viral proteins precursor transmembrane (PrM) and envelope (E). Vaccine
vials will be supplied at 4 mg/mL. Each DNA vaccination will be 1 mL of vaccine administered
intramuscularly (in deltoid muscle) using the Biojector 2000 Needle-Free Injection Management
System.
Subjects: Healthy adult volunteers (18 to 50 years old) will be enrolled.
Study Plan: Fifteen volunteers will be enrolled and receive 3 injections on the schedule
shown in the schema. The protocol requires nine clinic visits and three telephone follow-up
contacts.
Study Duration: 32 weeks clinical follow-up for each participant.
Study Endpoints: The primary endpoint is safety of the regimen; secondary immunogenicity
endpoints are an ELISPOT and an intracellular cytokine staining (ICS) assay for WNV-specific
T cell responses and a WNV ELISA assay. The principal timepoints for ICS and ELISPOT are Week
0 (baseline), Week 8 and Week 12. ICS and ELISPOT at other study timepoints, as well as other
immunogenicity assays through Week 32, will be completed as exploratory evaluations. Stored
sera will be tested for WNV neutralizing antibody once an assay is developed.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06052553 -
A Study of TopSpin360 Training Device
|
N/A | |
Completed |
NCT05511077 -
Biomarkers of Oat Product Intake: The BiOAT Marker Study
|
N/A | |
Recruiting |
NCT04632485 -
Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
|
||
Completed |
NCT05931237 -
Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults
|
N/A | |
Terminated |
NCT04556032 -
Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women
|
N/A | |
Completed |
NCT04527718 -
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04065295 -
A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225
|
Phase 1 | |
Completed |
NCT04107441 -
AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04998695 -
Health Effects of Consuming Olive Pomace Oil
|
N/A | |
Completed |
NCT01442831 -
Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects
|
Phase 1 | |
Terminated |
NCT05934942 -
A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood
|
Phase 1 | |
Recruiting |
NCT05525845 -
Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI
|
N/A | |
Completed |
NCT05515328 -
A Study in Healthy Men to Test How BI 685509 is Processed in the Body
|
Phase 1 | |
Completed |
NCT04967157 -
Cognitive Effects of Citicoline on Attention in Healthy Men and Women
|
N/A | |
Completed |
NCT05030857 -
Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects
|
Phase 1 | |
Recruiting |
NCT04494269 -
A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls
|
Phase 1 | |
Recruiting |
NCT04714294 -
Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT04539756 -
Writing Activities and Emotions
|
N/A | |
Recruiting |
NCT04098510 -
Concentration of MitoQ in Human Skeletal Muscle
|
N/A | |
Completed |
NCT03308110 -
Bioavailability and Food Effect Study of Two Formulations of PF-06650833
|
Phase 1 |